Beactica Initiates Drug Discovery Collaboration with Medivir
News Jun 10, 2014
Beactica has announced that it has entered into an agreement with Medivir AB. Under the agreement, Beactica will use its proprietary discovery platform to identify novel hits against a disease-relevant protease of therapeutic interest to Medivir. Financial terms of the agreement were not disclosed.
“We are pleased that Medivir has selected Beactica to advance one of their prioritized discovery programmes”, said Beactica CEO, Dr Per Källblad. “Medivir is at a very exciting point in their development and we are looking forward to tackle this challenging project together with their team of innovative scientists”.
Dr Richard Bethell, Executive Vice President Discovery Research, Medivir commented: “We at Medivir are very much looking forward to collaborating with our partners at Beactica, and applying their fragment-based lead discovery technology, in our search for hits active against one of our early discovery targets".
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE
A Greener Way to Make KetonesNews
Researchers at McGill University have discovered a new, more environmentally friendly way to make ketones, an important chemical ingredient in pharmaceuticals. While ketones are found in a wide range of useful chemicals, they are commonly prepared through energy-intensive, multi-step technologies that create significant chemical waste.READ MORE